GSK plc
Researches, develops and manufactures vaccines, specialty medicines and general medicines for disease prevention and treatment globally, with particular focus on oncology, respiratory conditions and immunology.
As of Oct 15, 2026
Summary
GSK plc is a London-listed pharmaceutical and vaccines company with a market capitalisation of £70.2 billion. The stock is trading at 1,816p and carries a bearish technical bias despite a solid one-year return of 15.5%, whilst the past month has seen a 2.0% decline. Today's move of 3.6% marks an intraday counter-trend shift against the broader downward technical reading.
Price history
As of Oct 14, 2026
Performance
+2.89%
+1.42%
-2.05%
-6.31%
+2.17%
+15.52%
As of Oct 14, 2026
Technical indicators
- 50
- -1.82Bearish
- 50: 1848.9 · 200: 1925.99Bearish
- 1,803p / 1,911p
Technical Bias
Bearish lean
GSK plc's technical picture leans bearish right now. The MACD sits negative at -1.82 whilst the 50-day moving average has dipped below the 200-day, both signalling downward momentum, though the RSI at 50 remains neutral. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 14, 2026
Fundamentals
- £70.2B
- 14.86
- 1.18p
- 14.52%
- +5.3%
- £5.96B
- 0.28
- 1,537p – 2,224p
- 3.84%
- Aug 13, 2026
- Oct 28, 2026 (12 days)
As of Oct 16, 2026
Upcoming catalysts
- Earnings report
As of Oct 16, 2026
Latest news
As of Oct 16, 2026
MonkeyTrade's Take on GSK plc
Short-term outlook
GSK's short-term setup leans bearish, with MACD in negative territory and both the 50-day and 200-day averages sitting above price, reinforcing the downward drift behind the 1-month -2.0% return. RSI at 50 keeps momentum neutral for now, so the next move hinges on the 1,803p support holding or giving way, with 1,911p resistance needing to break to shift the picture. No earnings catalyst is imminent, with the next report not due until October 2026.
Medium-term outlook
GSK's fundamentals look steady rather than exciting: 5.3% revenue growth, a 14.5% profit margin and a 3.8% dividend yield, all underpinned by a modest 14.86 price-to-earnings ratio, so the shares aren't priced for much optimism. Yet the technical lean is bearish, suggesting the market isn't rewarding that steadiness over the next few quarters. A pickup in revenue growth would be the key development to shift this cautious read.
Key risks
- GSK's growing reliance on external AI and research partnerships to fill its pipeline raises questions about how much value it can capture versus the partners it depends on.
- With a profit margin of 14.5% and revenue growth of 5.3%, the business has limited room for error if new drug candidates from these collaborations fail to progress or face delays.
- The stock trades well below its 52-week high of 2,224p at 1,816p, suggesting the market may be pricing in uncertainty around pipeline execution or broader healthcare sector pressures.
- Supply chain vulnerabilities flagged across the healthcare dividend sector could also weigh on GSK, given its scale of global manufacturing and distribution.
About GSK plc
GSK plc is a UK-based pharmaceutical group listed on the London Stock Exchange under the ticker GSK. Operating in the healthcare sector within the drug manufacturers industry, the company develops and supplies medicines, vaccines and other healthcare products, placing it among the UK's largest and most established players in the pharmaceutical space. With a market capitalisation of £70.2 billion, GSK ranks as a heavyweight on the London market, reflecting its broad operational scale and long-standing presence in the industry.
GSK's key figures give some sense of how the market currently views the business. A price-to-earnings ratio of 14.86 shows how its share price compares with recent earnings, while a dividend yield of +3.8% reflects the level of income the company currently returns to shareholders relative to its share price. Together, these figures offer a snapshot of how GSK is valued and rewarded by the market today.
How to trade GSK plc
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.